Cornerstone Pharmaceuticals
Cornerstone Pharmaceuticals is dedicated to developing innovative cancer therapies that target the metabolic foundation for tumor growth and harness the immune system to treat hard-to-treat cancers. Their mission is to improve the lives of people with significant medical unmet needs through science stemming from renowned institutions and compassionate efforts.
Industries
Nr. of Employees
small (1-50)
Patents
Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
US-11622950-B2
View DetailsMethods of treating leukemia using compositions containing bis(benzylthio)octanoic acid and ion pairs thereof
US-11065335-B2
View DetailsMethods of treating myeloma and lymphoma using compositions containing an ion pair of a lipoic acid derivative
US-9872845-B2
View Details
Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
US-11622950-B2
View DetailsMethods of treating leukemia using compositions containing bis(benzylthio)octanoic acid and ion pairs thereof
US-11065335-B2
View DetailsMethods of treating myeloma and lymphoma using compositions containing an ion pair of a lipoic acid derivative
US-9872845-B2
View DetailsProducts
Clinical-stage metabolism-directed small-molecule therapeutic
A clinical-stage small-molecule therapeutic designed to target mitochondrial and metabolic pathways in cancer cells; evaluated in multiple combination and indication-specific clinical trials and recognized by regulatory authorities with orphan-designation(s).
Pipeline of metabolism-directed oncology candidates
Portfolio of additional drug candidates at various preclinical and clinical stages focused on targeting cancer metabolic pathways, available for co-development or licensing.
Clinical-stage metabolism-directed small-molecule therapeutic
A clinical-stage small-molecule therapeutic designed to target mitochondrial and metabolic pathways in cancer cells; evaluated in multiple combination and indication-specific clinical trials and recognized by regulatory authorities with orphan-designation(s).
Pipeline of metabolism-directed oncology candidates
Portfolio of additional drug candidates at various preclinical and clinical stages focused on targeting cancer metabolic pathways, available for co-development or licensing.
Services
Evaluation of external research and assets for in-licensing; development and execution of joint drug development plans with inventors and institutions; pursuit of out-licensing or co-development arrangements for later-stage candidates and selected geographies.
Operational leadership and execution support for oncology clinical trials across phases, including multi-center coordination and progression to pivotal studies.
Management of physician-submitted expanded access requests through a standardized submission form and dedicated review contact to assess individual patient access to investigational therapies.
Evaluation of external research and assets for in-licensing; development and execution of joint drug development plans with inventors and institutions; pursuit of out-licensing or co-development arrangements for later-stage candidates and selected geographies.
Operational leadership and execution support for oncology clinical trials across phases, including multi-center coordination and progression to pivotal studies.
Management of physician-submitted expanded access requests through a standardized submission form and dedicated review contact to assess individual patient access to investigational therapies.
Expertise Areas
- Clinical trial management and execution
- Cancer metabolism-targeted therapeutics
- Regulatory strategy and designation
- CMC and manufacturing regulatory oversight
Key Technologies
- Mitochondria-targeting small-molecule therapeutics
- TCA-cycle and mitochondrial metabolism inhibition
- In vivo cancer models for efficacy testing
- Combination therapy development